Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Factors associated with Influenza vaccination rates among people with Multiple Sclerosis
Multiple Sclerosis
S40 - MS Diversity and Epidemiology (5:18 PM-5:30 PM)
010

Vaccination coverage against Influenza remains low especially among vulnerable populations. The rate of vaccination and the associated factors in pwMS  remain unknown. Identifying the factors associated with  vaccination is important for clinical practice and healthcare policies.

To evaluate influenza vaccination coverage and its predictors among patients with multiple sclerosis (pwMS)  in the UK.

This observational study included adult patients from Barts Health NHS Trust, London, UK with definite diagnosis of MS,  who were invited to complete an online survey about influenza vaccination between 2018-2019. Logistic regression analyses were performed to obtain predictors of influenza vaccination. 


Two hundred and five (205)  participants  (median age 46,IQR] 38-55, 70% female) completed the online survey, of whom 78% reported being vaccinated for that year. Previous vaccination was the only independent predictor for future vaccination (OR 1.39, 95% CI 1.28-1.51, p<0.001 ). Predictors of no vaccination were receiving no information about the vaccine (OR 0.84 95% CI 0.76-0.92),  fear of vaccination (OR 0.81, 95% CI 0.68-0.98) or MS related side effects (OR 0.65  95% CI 0.55-0.77),  being an anti-vaccine advocate (OR 0.6 95% CI 0.48-0.75), having had a past negative experiences with vaccination (OR 0.56 95% CI 0.47-0.66), having concerns on interaction with disease modifying therapies (OR 0.53 95% CI 0.39-0.73), or other non medical issues (OR 0.49 95% CI 0.42-0.57).


PwMS that have been previously vaccinated against influenza are 50% more likely to opt for future vaccination. Receiving no direct information about the vaccine, having fears of side effects or interactions, or having previous negative experiences are independent negative factors against vaccination. These are modifiable factors that could be addressed to increase vaccination rates in this population. 


Authors/Disclosures
Mariana Gaviria (Universidad Del Rosario)
PRESENTER
Ms. Gaviria has nothing to disclose.
No disclosure on file
Saul Reyes, MD (The Royal London Hospital) Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BIIB. Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Dr. Reyes has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen.
Aristides Duque, MD Dr. Duque has nothing to disclose.
Gavin Giovannoni, MD (QMUL) Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Japanese Tobacco. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aurinia Pharmaceuticals. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Oxford Health Policy Forum. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Peervoice. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Bristows .